Clinigen Group PLC (LON:CLIN) has earned a consensus rating of “Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is GBX 1,222.17 ($16.89).
CLIN has been the subject of several recent analyst reports. Peel Hunt reissued a “buy” rating and set a GBX 1,350 ($18.65) price objective on shares of Clinigen Group in a report on Tuesday, October 31st. Berenberg Bank initiated coverage on shares of Clinigen Group in a report on Wednesday, November 1st. They set a “hold” rating and a GBX 1,200 ($16.58) price objective for the company. Royal Bank of Canada reissued an “outperform” rating and set a GBX 1,360 ($18.79) price objective on shares of Clinigen Group in a report on Tuesday, November 7th. N+1 Singer reissued a “buy” rating and set a GBX 1,225 ($16.92) price objective on shares of Clinigen Group in a report on Wednesday, November 29th. Finally, Numis Securities reissued an “add” rating and set a GBX 1,208 ($16.69) price objective on shares of Clinigen Group in a report on Wednesday, January 17th.
In other news, insider Chris Rigg sold 4,955 shares of Clinigen Group stock in a transaction dated Thursday, November 23rd. The shares were sold at an average price of GBX 1,017 ($14.05), for a total value of £50,392.35 ($69,621.93).
Shares of Clinigen Group (CLIN) traded down GBX 2 ($0.03) during mid-day trading on Thursday, reaching GBX 1,035 ($14.30). 200,641 shares of the company’s stock traded hands, compared to its average volume of 393,485. The firm has a market cap of $1,270.00 and a price-to-earnings ratio of 34,500.00. Clinigen Group has a 52 week low of GBX 751.50 ($10.38) and a 52 week high of GBX 1,187 ($16.40).
TRADEMARK VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/20/clinigen-group-plc-clin-receives-gbx-1222-17-average-pt-from-analysts.html.
About Clinigen Group
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.